Effects of rebamipide on aspirin-induced gastric damage

Dammann, Hanns Gerd

doi:10.1097/00042737-199410000-00013

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, like a human case-control study (32), rebamipide proved to have anti-ulcer actions in rats. In addition, although rebamipide was reported to accelerate healing of hydrochloric acid-induced and indomethacininduced gastric mucosal injury (21), the present study demonstrated that rebamipide is effective for acetic acidinduced gastric ulcer, as described previously (31); the ulcer index at each time-point was significantly smaller in the rebamipide group than in the control group.…”

Section: Discussionsupporting

confidence: 65%

Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor

Udagawa

Shiota

Ichiba

et al. 2003

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 65%

Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor

Udagawa

Shiota

Ichiba

et al. 2003

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…The prophylactic effect of rebamipide on aspirininduced gastric lesions have been already evaluated by Damman et al (44) in clinical study. However, the protective mechanisms of rebamipide on aspirininduced gastric hemorrhagic lesions were not elucidated so far.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesions and Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution

et al. 2008

View full text Add to dashboard Cite

Abstract. Aspirin and nonsteroidal anti-inflammatory agents are known to induce gastroduodenal complications such as ulcer, bleeding, and dyspepsia. In this study, we examined the prophylactic effect of rebamipide, an anti-ulcer agent with free-radical scavenging and antiinflammatory effect, on acidified aspirin-induced gastric mucosal injury in rats. In addition, we investigated the mucosal barrier functions disrupted by aspirin. Oral administration of acidified aspirin resulted in linear hemorrhagic erosions with increasing myeloperoxidase activity and thiobarbituric acid-reactive substance concentrations in the gastric mucosa. Rebamipide suppressed these acidified aspirin-induced gastric lesions and inflammatory changes significantly, and its protective effect was more potent in the case of repeated (twice daily for 3 days) treatment than single treatment before aspirin administration. Immunostaining of zonula occludens (ZO)-1, one of the tight junctional proteins, was strengthened in rat gastric mucosa after repeated administration of rebamipide. In addition, aspirin induced the increasing transport of fluorescine isothiocyanate-labeled dextrans with localized disruption and decreased expression of ZO-1 protein on rat gastric mucosal cell line RGM-1. Rebamipide effectively prevented aspirin-induced permeability changes and disruption of ZO-1 distribution. These results suggest that rebamipide protects against aspirin-induced gastric mucosal lesions by preserving gastric epithelial cell-to cell integrity in addition to the anti-inflammatory effects.

show abstract

“…[2][3][4] Rebamipide was also found to be efficacious in reducing gastric injury in healthy subjects taking aspirin 1500 mg once a day. [5] However, there are not enough data concerning the efficiency of rebamipide in the prevention of NSAID-induced gastrointestinal lesion.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Rebamipide in Prevention of NSAID-Gastropathy

Ткач¹,

Onischuk²,

Балабанцева³

2017

Int J Biomed

View full text Add to dashboard Cite

Background: Nonsteroidal anti-inflammatory drugs (NSAID) are one of the most widely used drugs in medical practice. However, all medical benefits of NSAID are paid for by increased risk of developing numerous side effects. One of the most clinically significant side effects is a NSAID-induced gastrointestinal lesion that develops in, on average, 30% of NSAID users, even with the absence of ulceration; NSAID-induced ulcers and bleeding cause 61% of deaths related to side effects of these medicines. The main aim of this study was to compare the incidence of erosive and ulcerative lesions of the gastroduodenal zone as a result of patients receiving diclofenac on the background of concomitant prophylactic use of proton pump inhibitor (PPI) omeprazole or rebamipide.Materials and Methods: To achieve this goal we have conducted a randomized comparative study, which included 118 patients aged from 25 to 65 years (mean age, 45±18 years) with osteoarthritis (94 patients) and rheumatoid arthritis (24 patients), who had taken a once-daily dose of 100 mg diclofenac (Dikloberl) over 1 month. Depending on the treatment, all patients were randomized into 3 groups by using the computer method of random numbers. Within 1 month, patients of Group 1 (n=42) received additionally a once-daily dose of 20 mg omeprazole (Omez), and patients of Group 2 (n=46) -rebamipide at a dose of 100 mg three times a day. Patients of Group 3 (n=30) received only diclofenac. The primary endpoint was the cumulative incidence of development of erosions and ulcers in the gastroduodenal zone, which was determined after the treatment according to data from the endoscopy. The secondary endpoint was the incidence of development of dyspeptic symptoms and side effects.Results: During 1 month of continuous reception of diclofenac, peptic ulcers of stomach and duodenum were found in 2/4.8% and 2/4.8% patients of Group 1 and in 3/6.5% and 2/4.3% patients of Group 2, respectively. In Group 3, peptic ulcers of stomach and duodenum were found in 5/16.6% and 3/10% patients, respectively, and in 2 cases, these ulcers (1 gastric ulcer and 1 duodenal ulcer) have manifested into gastrointestinal bleeding. Thus, all peptic ulcers of the gastroduodenal area were detected in 4/9.5% patients of Group 1, 5/10.9% patients of Group 2, and 8/26.6% patients of Group 3. (Int J Biomed. 2017; 7(1):57-59.)

show abstract

Effects of rebamipide on aspirin-induced gastric damage

Cited by 6 publications

References 0 publications

Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor

Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor

Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesions and Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution

Efficacy and Safety of Rebamipide in Prevention of NSAID-Gastropathy

Contact Info

Product

Resources

About